Skip to content
Calculator
Regulation

The 2026 peptide enforcement timeline

Last updated: November 4, 2026 · 6 min read · By the Grey Peptides Editorial Board

A judge signing documents at a desk, with a gavel in the foreground
Photo by Katrin Bolovtsova on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • In 2026 the FDA moved in two directions at once. It took 12 peptides off its formal safety-concern list after their nominations were withdrawn, by an April 15 notice that a law-firm report describes 4 3, and it sent warning letters in August and September to online sellers and a compounding pharmacy 1 11.
  • Research-use labels did not protect sellers. Five warning letters dated August 24 said the sellers' own websites showed the products were drugs for people, whatever the label said 1.
  • Two decisions were still open at our last check on October 27, 2026: whether FDA will act on the compounding committee's July votes for six peptides, and its final word on keeping semaglutide, tirzepatide and liraglutide off the 503B list 5 7.

How this timeline works

This is a record of what US government bodies did about peptides in 2026, each entry dated and tied to a government document; where an agency document is no longer posted or was never posted (the April 15 notice, the committee's vote tallies), we say so and name the published reports we rely on. It leaves out rumours and seller announcements. A warning letter is the FDA's formal notice that it considers a company to be in violation of the law; it is not a court finding, and companies are asked to respond 1. Each status below is as of the date given.

Late 2025: the lead-in

December 19, 2025. In a warning letter about children's "growth" supplements that contained undeclared ibutamoren, the FDA stated that ibutamoren (MK-677) is excluded from the definition of a dietary supplement and that it may increase the potential for congestive heart failure in certain individuals 2. Ibutamoren is not a peptide, but our encyclopedia covers it beside them, and the letter set out the agency's position before the year began.

April to June: the Category 2 reset and the GLP-1 proposal

April 15, 2026. According to a law-firm analysis published the next day, the FDA updated its list of bulk drug substances nominated for compounding under section 503A, giving notice that after seven days it would remove 12 peptides from Category 2, the group it treats as raising significant safety concerns, because their nominations had been withdrawn 3. That notice is no longer on the FDA's pages; its Category 2 page, current as of April 22, 2026, now lists BPC-157 Low and TB-500 Low among substances whose nominations were withdrawn 4. Leaving Category 2 did not put them on the 503A bulks list or into Category 1, the group where the FDA uses enforcement discretion, which left them in what the analysis called a regulatory gray area 3 5.

April 16, 2026. A Federal Register notice announced that the Pharmacy Compounding Advisory Committee would meet on July 23 and 24 to discuss seven peptides for the 503A bulks list: BPC-157, KPV, TB-500 and MOTS-c on the first day, emideltide, semax and epitalon on the second (91 FR 20465) 6.

May 1, 2026. The FDA proposed not to include semaglutide High, tirzepatide High and liraglutide on the 503B bulks list, the list outsourcing facilities can compound from, with a 60-day comment period (91 FR 23431, published May 1; FDA's announcement is dated April 30) 7. It was a notice, not a rule.

June 26, 2026. A two-page Federal Register notice extended the comment period by thirty days, to July 30, 2026 (91 FR 38719) 8.

June 29, 2026. The FDA released one briefing document per peptide ahead of the committee meeting. In each, agency staff proposed not adding the substance to the 503A list; across the seven, they cited inadequate chemical characterisation, missing information on immune reactions, insufficient evidence of effectiveness and, for some, approved therapies already available for the nominated uses 9.

July: the committee votes

July 23 and 24, 2026. The Pharmacy Compounding Advisory Committee recommended six of the seven peptides for the 503A list, against the FDA staff's proposals. The FDA has posted no minutes or tallies (its meeting page was last updated August 6, 2026) 9, so the counts are as reported: BPC-157, KPV and TB-500 each by 8 votes to 6 with one abstention, MOTS-c by 7 to 5 with two abstentions, semax by 8 to 5, and epitalon (reports differ on its "no" count). It voted down emideltide, also called DSIP, by 6 to 7 10. The committee advises; it does not decide.

July 30, 2026. The comment period on the 503B GLP-1 proposal closed 8.

August and September: the warning letters

August 24, 2026. The FDA's drug center sent warning letters to five online peptide sellers in North Carolina, Florida, Texas and Arizona, and posted them on September 1. Each letter calls the named products unapproved new drugs whose sale across state lines violates sections 301(d) and 505(a) of the Food, Drug, and Cosmetic Act. Each also rejects the same defence: labels describing the products as for research or laboratory use, not for human use, did not outweigh what the sellers' websites showed. The products named across the letters include semaglutide, tirzepatide and retatrutide, often under grey-market nicknames, along with survodutide, mazdutide, SS-31, PT-141, tesamorelin and a tesamorelin-ipamorelin blend 1.

September 18, 2026. In a warning letter posted September 22, the FDA told a Houston compounding pharmacy that its tirzepatide with niacinamide and semaglutide with cyanocobalamin (vitamin B12) "appear to be essentially copies" of FDA-approved semaglutide and tirzepatide products, and that the volume it was producing suggested the claimed differences from the approved products were pretextual. FDA investigators had inspected the pharmacy from November 3 to 14, 2025 11.

Where things stand

October 30, 2026. HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157, TB-500, MOTS-c, KPV, semax and epitalon under the forms, routes and conditions in its Appendix B 12. The policy is non-binding, labelled a draft and open to revision; FDA has not added any of them to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).

At our last check on October 27, 2026, none of the six peptides the committee recommended was in Category 1 of FDA's 503A list (still dated May 14, 2026), so the legal position for pharmacies was the one that applied before the vote, and no final determination on the 503B GLP-1 proposal had appeared in the Federal Register 5 7. For what these rules mean for anyone buying peptides online, see our guide to what "research use only" means; for compounded GLP-1 users, our GLP-1 transition guide covers the options.

Frequently asked questions

Did the FDA legalise BPC-157 in 2026?

No. According to a law-firm report, on April 15, 2026 the FDA gave notice that BPC-157 and 11 other peptides would leave Category 2, but that did not put them on the 503A bulks list or into Category 1. The compounding committee recommended BPC-157 in July; at our last check on October 27, the FDA had not acted on that vote.

What did the FDA warning letters to peptide sellers say?

Five letters dated August 24, 2026 said the products named were unapproved new drugs and that labels calling them research or laboratory products not for human use did not outweigh what the sellers' own websites showed.

Can compounding pharmacies still make semaglutide and tirzepatide?

The FDA proposed on May 1, 2026 not to put them on the 503B list, and its comment period closed July 30. In September it also told a compounding pharmacy that its vitamin-added GLP-1 products appeared to be essentially copies of the approved drugs. At our last check on October 27, the final 503B decision had not been published.

Is a warning letter a conviction?

No. A warning letter is the FDA's formal notice that it considers a company to be in violation of the law. It is not a court ruling, and the company is asked to respond.

Sources

  1. US FDA. Warning letters 733652, 734884, 735063, 735067 and 735127, dated August 24, 2026, to five online peptide sellers, posted September 1, 2026 (one of the five linked; letter 733652 re-read October 27, 2026: CDER, sections 301(d) and 505(a), labeling 'for laboratory, research, and analytical use' and 'not intended for human or veterinary use'). FDA warning letter, August 2026
  2. US FDA. FDA warning letter 718252, December 19, 2025: children's growth supplements containing undeclared ibutamoren mesylate; ibutamoren excluded from the dietary supplement definition. Read October 27, 2026. FDA warning letter, December 2025
  3. Orrick, Herrington & Sutcliffe. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings, April 16, 2026: FDA gave notice on April 15 that 'after 7 days, it will remove 12 peptide bulk drug substances from Category 2', nominations 'withdrawn by the nominators'; removal does not by itself place them on the 503A list or in Category 1. Read October 27, 2026.
  4. US FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: 'Bulk drug substances nominated but withdrawn' (17 substances, including BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'); content current as of April 22, 2026; read October 27, 2026. No withdrawal date is given. FDA
  5. US FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026): none of BPC-157, KPV, TB-500, MOTS-c, semax or epitalon in Category 1; read October 27, 2026. FDA
  6. Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting (FDA, April 16, 2026; 91 FR 20465, document 2026-07361); read October 27, 2026. Federal Register
  7. US FDA. FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (press announcement April 30, 2026; notice published May 1, 2026, 91 FR 23431, document 2026-08552, comments to June 30); read October 27, 2026. A Federal Register search on October 27, 2026 found no later FDA document on these substances and 503B. FDA
  8. Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B: extension of the comment period to July 30, 2026, June 26, 2026 (91 FR 38719); read October 27, 2026. Federal Register
  9. US FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026 meeting page: seven briefing documents (released June 29, 2026), questions, agenda, roster and presentations; no minutes or vote tallies posted (content current as of August 6, 2026); read October 27, 2026. FDA
  10. McDermott (law firm). PCAC backs majority of peptides in two-day public meeting (July 27, 2026): tallies for all seven; read October 27, 2026. Other reports agree on every tally except epitalon's 'no' count (7-4-1 here and in the FDA Law Blog; 7-5-1 in RAPS Regulatory Focus).
  11. US FDA. Warning letter 738238 to a Houston compounding pharmacy, September 18, 2026, posted September 22, 2026; read October 27, 2026. FDA warning letter, September 2026
  12. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead